Premarin Progetstin Therapy Doubles Cancer Death Rate

by | Oct 8, 2009


A green chalkboard with the message 'I LOVE YOU' written in white chalk.Synthetic hormone replacement therapy, already linked to increased risk of breast cancer, heart disease stroke, and dementia, nearly doubles a woman’s risk of dying from lung cancer.


This new research, published September 18, 2009, found that there were 83% more deaths in the group using Premarin plus Progestin hormone therapy than the group using the placebo. (Lancet. 2009 Sep 18. Epub ahead of print)


“This is a new, lethal side effect of Estrogen plus Progestin use,” said Dr. Rowan Chlebowski lead author of the study, from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.


This latest bad news about standard hormone therapy comes on the heels of a study published in February 2009, in the New England Journal of Medicine, that found that women who take Estrogen-Progestin combination hormone therapy for more than five years suffer a doubling of their risk of getting breast cancer and the risk doubles again every year they continue to take the drugs.


In 2004, researchers found that Estrogen-Progestin drugs not only did not prevent Alzheimer’s as was previously thougt, but actually increased the risk of dementia and mental decline by 47%. Thirty-five million Americans now have dementia.


In 2002, the results of the Women’s Health Initiative, reported that Premarin plus synthetic Progesterone increased a women’s risk of breast cancer by 26%, her risk of a heart attack by 29%, her risk of stroke by 41% and her risk of blood clots by 113%.


Collectively, these findings should end the debate as to whether or not the risks of these drugs are worth the benefits.


Why Don’t Doctors or the FDA send out Recall Notices?


Despite previous warnings – increased risks of heart attacks, stroke, invasive breast cancer, pulmonary emboli, blood clots, gall bladder disease and dementia – millions of postmenopausal women still use the combined hormone therapy to fight the symptoms of menoupause.


Dr. Chlebowski says that 25 to 30 million hormone prescriptions are written every year that are probably responsible for half of the 40,000 breast cancers discovered in women every year.


Perhaps women are not seeing the headlines or hearing the news. Perhaps their doctors should be required to send them a RECALL NOTICE, rather than continue to refill their prescriptions.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

12 + 12 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });